X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Pharmacological Reports

期刊標題檢索 PHARMACOL REP 最新評論: Afterwards, comparison is the testing of non-research hypotheses. It i... (2021-12-30)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Pharmacological Reports]您好,您是該頁面的第 33050 位訪客。

期刊簡介
期刊名稱Pharmacological Reports Pharmacological Reports
LetPub Score
6.3
50 ratings
Rate

Reputation
7.6

Influence
5.1

Speed
7.0

期刊簡稱PHARMACOL REP
ISSN1734-1140
E-ISSN2299-5684
h-index71
CiteScore
CiteScoreSJRSNIPCiteScore Rank
8.400.8670.940
Subject fieldQuartilesRankPercentile
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Pharmacology
Q159 / 313

自引率 (2023-2024)0.00%自引率趨勢
掲載範囲
Pharmacological Reports publishes articles concerning all aspects of pharmacology, dealing with the action of drugs at a cellular and molecular level, and papers on the relationship between molecular structure and biological activity as well as reports on compounds with well-defined chemical structures.
Pharmacological Reports is an open forum to disseminate recent developments in: pharmacology, behavioural brain research, evidence-based complementary biochemical pharmacology, medicinal chemistry and biochemistry, drug discovery, neuro-psychopharmacology and biological psychiatry, neuroscience and neuropharmacology, cellular and molecular neuroscience, molecular biology, cell biology, toxicology.
Studies of plant extracts are not suitable for Pharmacological Reports.
官方網站https://www.springer.com/43440
在線稿件提交https://www.editorialmanager.com/prep/default.aspx
開放訪問No
出版商Springer International Publishing
主題領域医学
出版國/地區POLAND
發行頻率隔月刊行
創刊年2009
每年文章數114每年文章數趨勢
黃金OA百分比42.82%
Web of Science 四分位
2023-2024
WOS Quartile: Q2

CategoryEditionJIF QuartileJIF RankingJIF Percentage
PHARMACOLOGY & PHARMACYSCIEQ294/354
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1734-1140%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: About 6.0 month(s)
競爭力 *來自作者的數據: Moderate
參考鏈接
相關期刊 【Pharmacological Reports】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    PHARMACOLOGICAL REVIEWSH-index: 210

    CiteScore: 34.70
    DRUG RESISTANCE UPDATESH-index: 100

    CiteScore: 26.20
    ADVANCED DRUG DELIVERY REVIEWSH-index: 278

    CiteScore: 28.10
    TRENDS IN PHARMACOLOGICAL SCIENCESH-index: 201

    CiteScore: 23.90
    PHARMACOLOGY & THERAPEUTICSH-index: 180

    CiteScore: 23.00
    MEDICINAL RESEARCH REVIEWSH-index: 119

    CiteScore: 29.30
    PHARMACOLOGICAL RESEARCHH-index: 118

    CiteScore: 18.70
    ARCHIVES OF PHARMACAL RESEARCHH-index: 75

    CiteScore: 13.40
    BIOMEDICINE & PHARMACOTHERAPYH-index: 78

    CiteScore: 11.90
    BRITISH JOURNAL OF PHARMACOLOGYH-index: 190

    CiteScore: 15.40
    學科內最受檢索的期刊 頁面查看次數
    BIOMEDICINE & PHARMACOTHERAPY498329
    PHYTOMEDICINE340268
    LIFE SCIENCES285763
    International Journal of Pharmaceutics242440
    PHARMACOLOGICAL RESEARCH241281
    European Journal of Pharmacology204248
    BIOCHEMICAL PHARMACOLOGY202693
    JOURNAL OF NATURAL PRODUCTS196695
    BRITISH JOURNAL OF PHARMACOLOGY165140
    MOLECULAR PHARMACEUTICS162833
  •  

    Pharmacological Reports Pharmacological Reports
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [Pharmacological Reports] 的評論撰寫評論
作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 23:05:26 評論於
Afterwards, comparison is the testing of non-research hypotheses. It is very common in actual research: I have completed the experiment, verified the hypothesis, but still need to extend the research, which requires further exploration of the data to see which direction will yield valuable conclusions. At this point, it is as if I am testing all possible comparisons (even though I may not actually exhaust all comparisons, but because there is no specific purpose, all comparisons are potential). Because comparison does not only refer to the difference in means of two treatments, linear combinations of multiple treatments are also comparisons
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 22:11:39 評論於
Choose the post hoc test method based on the data results obtained
(0) 讚! | 维尔娜菲茨杰拉德

作者: 上清雨真


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 20:07:14 評論於
Why do we need to conduct post-inspections?
(0) 讚! | 上清雨真

作者: 北国博达


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-27 20:10:01 評論於
What kind of post-test should I use?
(0) 讚! | 北国博达

作者: 八荒沛容


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-12-05 10:38:38 評論於
Shouldn't it be $3000 directly? I saw it on the official website
(0) 讚! | 八荒沛容

作者: 宗室向凝


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-12-03 21:01:42 評論於
How is the layout fee calculated?
(0) 讚! | 宗室向凝

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-07-18 19:32:18 評論於
There has been an increase, optimistic about the future, what do you think?
(0) 讚! | 凌霄高洁

作者: 白卉大叔


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-02-10 11:23:23 評論於
Review speed: 1.0 | Submission acceptance rate: 75.0
Sharing experience: The journal editor is very meticulous and patient in helping to make some revisions, and another paper was accepted today
(0) 讚! | 白卉大叔

作者: 白卉大叔


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2015-11-04 09:19:37 評論於
Review Speed: 3.0 Experience sharing: I received an acceptance email yesterday (2015.11.3) for a bimonthly journal, but I am not sure when it will be published online
(0) 讚! | 白卉大叔

作者: 匿名


領域: 医药科学
審稿時間: 0.0 month(s)
結果:


撰寫評論

2012-08-27 19:41:00 評論於
This journal is a bimonthly journal. The first review is slow, it takes about 3-4 months, but the editor is very polite. The main publication focuses on molecular pharmacology research. As long as the research is creative, and the English writing is OK, you should be okay

(0) 讚! | 匿名

作者: 墟散远骞


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2012-08-27 10:46:45 評論於
The magazine is a bimonthly publication, with a slow review speed of about 3-4 months, but the editors are very polite. It mainly publishes research on molecular pharmacology, and as long as the research is creative and well-written in English, papers that are not in a rush to be published can choose to submit to this journal
(0) 讚! | 墟散远骞

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2012-01-10 10:09:28 評論於
It's a long period of time
(0) 讚! | 凌霄高洁

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2011-10-06 23:10:51 評論於
I submitted an article this year, but it was rejected after the initial review that lasted for 5 months
(0) 讚! | 凌霄高洁

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2011-04-19 19:26:59 評論於
Review Speed: 6.0 Sharing of Experience: I submitted a paper last year, which went through a nearly 3-month initial review and major revisions. However, it was accepted after the revisions. Personally, I feel that the editor was very kind
(0) 讚! | 凌霄高洁

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2010-12-03 13:05:46 評論於
Bi-monthly, very slow. First review cycle takes over 3 months
(0) 讚! | 凌霄高洁

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [Pharmacological Reports] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*